Leeds United will field a heavily rotated side for their FA Cup fourth round clash at home to Millwall on Saturday, Daniel ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...